Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
Christopher D. Brown filed an initial Statement of Beneficial Ownership (Form 3) for 908 Devices (MASS) following his appointment as Director. The filing reveals significant equity holdings as of June 13, 2025:
- Direct Common Stock ownership: 962,122 shares
- Stock Options: Total of 320,404 shares at various exercise prices ranging from $1.75 to $16.66, with different vesting schedules
- Restricted Stock Units (RSUs): 52,837 units vesting over four annual installments from 2022-2024
The stock options include both fully vested options and those with future vesting schedules through 2025. RSUs represent contingent rights to receive common stock upon vesting, with no expiration date. This substantial equity position aligns the director's interests with shareholders and indicates a long-term commitment to the company.
Michael S. Turner, Chief Legal & Administrative Officer of 908 Devices (MASS), executed a series of planned stock sales under a Rule 10b5-1 trading plan over three consecutive days in June 2025:
- June 16: Sold 16,082 shares at weighted average price of $7.5139
- June 17: Sold 7,148 shares at weighted average price of $7.506
- June 18: Sold remaining 1,373 shares at $7.50
The transactions resulted in a complete liquidation of Turner's direct common stock holdings, reducing his position from 24,603 shares to zero. All sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by determining the timing and terms of trades in advance.